Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.…
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
Opus Genetics (NASDAQ: IRD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 27 employees.
The shares were at 3.990 USD on 20 November 2026, up 99.5% over 52 weeks. Its 52-week range is 1.700 USD to 7.070 USD: the price is 43.6% below the high and 134.7% above the low.
Its market capitalisation is 385.65M USD.
Opus Genetics reports return on equity of -323.1% and revenue down 63.1% year over year.
It holds more cash than debt, a net cash position of 53.09M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 17 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 13.94 USD is 249.4% above the current price. The next earnings report is expected on 4 March 2027.